In summary, shAPE1‐loaded HCC827R‐CSC‐EVs could reduce the resistance of NSCLC cells to Erlotinib in vivo by activating the IL‐6/STAT3 signalling. Here, STAT3 is linked to non-small cell lung carcinoma.